PowerPoint Presentation

MAY 5TH, 2016 | NEW ORLEANS

J. Mike JudyCEODallas, TX

Evolution of The VisAbility Surgical Equipment and Procedure

Latest systematic approach allows for a simplified procedure and delivers secure, uncomplicated, and consistent placement of the scleral implants:

Precise Placement and Superior StabilitySurgery is significantly easier compared to prior years procedureGreater consistency of outcomes and long-term efficacy Experienced surgeons can complete surgery in less than 15 minutesLow incidence of adverse events

VIS Scleratome VIS Docking Station Implant (3rd Gen) with locking insert

VisAbility Implant System (VIS) ProcedureStep 1: Place the VIS docking station

Step 2: Create the scleral tunnel

Step 3: Place the VIS implant using shuttle/tubing

Step 4: Lock the VIS implant in place

The VisAbility Implant System is an investigational device and is limited by United States law to investigational use.

3

FDA Trial Recruitment ProgressPivotal Phase Recruitment Complete# of primary eye patient surgeries# of sites actively recruitingConfidential

Investigators are Key Opinion Leaders with Extensive Clinical Trials ExperienceClinical Trials Experience:AcuFocusApril 2015 FDA approvalReVision OpticsPending FDA approvalCalhoun Vision6/2015 $69mm private raiseGlaukos6/2015 $118mm IPOWaveTec8/2014 acquired by Alcon IntraLase3/2007 $800m+ acquisition by AMOKeraVison - INTACS1999 FDA approvalEditorial Board Members of:Cataract and Refractive Surgery TodayReview of OphthalmologyEyeWorldRefractive Eye CareKen Beckman(Columbus, OH)Frank Bucci (Wilkes-Barre, PA)Ralph Chu (Bloomington, MN)Alan Faulkner (Honolulu, HI)Jim Katz(Des Plaines, IL)Jodi Luchs(Wantaugh, NY)John Meyer (Louisville, KY)David Schanzlin (San Diego, CA)Karl Stonecipher (Greensboro, NC)Dan Tran (Orange County, CA)Kevin Waltz (Indianapolis, IN)Jeff Whitman (Dallas, TX) Oday Alsheikh (San Antonio, TX)

5

Jim Katz, MD Des Plaines, IL David Schanzlin, MD San Diego, CA William Trattler, MD Miami, FL Kevin Waltz, MD Indianapolis, IN Frank Bucci MD Wilkes-Barre, Pa George Waring, MD Charleston, SC Bill Wiley, MD Cleveland, OH Oday Alsheikh, MD San Antonio, TX Ralph Chu, MD Bloomington, MN Karl Stonecipher, MD Greensboro, NC John Meyer, MD Louisville, KY

VIS Scleratome Data Prior FDA StudyDCNVA at 40cm (excludes VIS Docking Station)% of patients with DCNVA of 20/40 or betterConfidentialThe VisAbility Implant System is an investigational device and is limited by United States law to investigational use.

Prior FDA Study All EyesDCNVA at 40cm (excludes VIS Docking Station)% of patients with DCNVA of 20/40 or betterConfidentialThe VisAbility Implant System is an investigational device and is limited by United States law to investigational use.

Percentage of Eyes Achieving 20/40 (J3) or Better Distance Corrected Near Visual Acuity @ 40cm Sloan EDTRS Chart (Single Site)(All Eyes, n=20)Data through March 4th, 2016ConfidentialThe VisAbility Implant System is an investigational device and is limited by United States law to investigational use.

8

Percentage of Eyes Achieving 20/40 (J3) or Better Uncorrected Near Visual Acuity @ 40cm Sloan EDTRS Chart (Single Site)Data through March 4th, 2016ConfidentialThe VisAbility Implant System is an investigational device and is limited by United States law to investigational use.

9

Describe the change in closeup visual performance after surgery without glasses as compared to before surgery without glasses (Single Site)Data through January 3rd, 2016ConfidentialThe VisAbility Implant System is an investigational device and is limited by United States law to investigational use.

Clinical / Regulatory Timeline

Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2201620172018Q3: FDA submissionMarch 23rd: FDA trial enrollment completeQ1: Patient follow-up complete1H:FDA approval and start of U.S. salesConfidential

25 years of shared experienceGlare & HalosContrast Sensitivity LossGhosting & Waxy VisionDysphotopsiaMissing the Refractive TargetDiplopiaInduced AberrationOptic Decentration and TiltDecrease Vision Quality in Mesopic Conditions

Loss of Depth PerceptionCompromised StereopsisExtensive NeuroadaptationAnisometropiaDistance Vision SacrificeCornea Haze / OpacificationStromal Necrosis Risk of Corneal MeltThe Patient in Lane 3 is dealing with . . . Confidential

Benefits of the VisAbility Procedure Over Other Surgical Options

Better Patient OutcomesOnly natural binocular solutionPreserves stereopsisProvides a Full Range of Focus, without CompromiseNot a monovision, bifocal, or multifocal solutionRestores functionality of the complete accommodative reflexPresbyopia reversal without sacrificing image qualitySuperior Safety ProfileNo major side effects, as seen in other presbyopia surgeriesLower risk of serious complicationsNo long-term complications (e.g., retinal detachments, corneal melt)Outside of Visual Axis & ReversibleCrystalline lens remains intactCornea shape and integrity unaffectedImplants can be removed

Confidential

MAY 5TH, 2016 | NEW ORLEANS

All Gain . . No Loss!

See the procedure in a new light . . . because your patients will!

Thank You.